KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Revenue (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Revenue for 8 consecutive years, with $71.7 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 51.04% to $71.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $277.0 million through Dec 2025, up 54.77% year-over-year, with the annual reading at $277.0 million for FY2025, 54.77% up from the prior year.
  • Revenue hit $71.7 million in Q4 2025 for Adaptive Biotechnologies, down from $94.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $94.0 million in Q3 2025 to a low of $7.7 million in Q2 2023.
  • Historically, Revenue has averaged $46.2 million across 5 years, with a median of $43.4 million in 2022.
  • Biggest five-year swings in Revenue: tumbled 82.36% in 2023 and later surged 460.91% in 2024.
  • Year by year, Revenue stood at $37.9 million in 2021, then surged by 45.53% to $55.2 million in 2022, then fell by 17.05% to $45.8 million in 2023, then increased by 3.66% to $47.5 million in 2024, then skyrocketed by 51.04% to $71.7 million in 2025.
  • Business Quant data shows Revenue for ADPT at $71.7 million in Q4 2025, $94.0 million in Q3 2025, and $58.9 million in Q2 2025.